Search by conditions:

 

Protocol Description Phase
16-183 A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects with Advanced Tumors  (View details on clinicaltrial.gov) Phase I
14-089 A Phase 1b/2 Study of Ramucirumab in Combination with LY2875358 in Patients with Advanced Cancer  (View details on clinicaltrial.gov) Phase II
13-251 A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the Fibroblast Growth Factor Receptor (FGFR) 1, 2 or 3 Genes  (View details on clinicaltrial.gov) Phase I
16-212 An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase II
4 clinical trials listed

Back to Top